Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	177931-17-8
Formula :	C₂₀H₂₀O₆
M.W :	356.37
SMILES Code :	O=C1C=C(OCO2)[C@]32OC4=C(C=C5C(OCO5)=C4)[C@@]6([H])[C@]3([H])[C@@]1([H])C[C@@H](C)[C@@H]6C
MDL No. :	MFCD08702698
InChI Key :	GMTJIWUFFXGFHH-WPAOEJHSSA-N
Pubchem ID :	11725801

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319
Precautionary Statements:	P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Human dermal fibroblasts	4 µM	12 days	Reduced mitochondrial ROS levels	Antioxidants (Basel). 2025 Feb 24;14(3):259
Raw264.7 cells	1–30 µM	1–18 hours	Inhibited LPS-induced iNOS, TNF-α, and COX-2 expression by suppressing I-κBα phosphorylation, p65 nuclear translocation, and C/EBP and/or AP-1 activation	Br J Pharmacol. 2003 May;139(1):11-20
Raw264.7 cells	1–30 µM	1–18 hours	Sauchinone inhibited LPS-inducible iNOS, TNF-α, and COX-2 expression through suppression of I-κBα phosphorylation and p65 nuclear translocation and of C/EBP and/or AP-1 activation.	Br J Pharmacol. 2003 May;139(1):11-20
Human dermal fibroblasts	1 µM	12 days	Restored mitochondrial function and reduced ROS levels	Antioxidants (Basel). 2025 Feb 24;14(3):259
Human dermal fibroblasts	1 µM	12 days	To evaluate the effect of Sauchinone on cell proliferation, results showed 1 µM Sauchinone significantly increased cell proliferation	Antioxidants (Basel). 2025 Feb 24;14(3):259
Human dermal fibroblasts	4 µM	12 days	To evaluate the effect of Sauchinone on mitochondrial ROS levels, results showed Sauchinone significantly reduced mitochondrial ROS levels	Antioxidants (Basel). 2025 Feb 24;14(3):259
HepG2 cells	30 µM	12-24 hours	Sauchinone significantly increased the mRNA and protein levels of GCL and NQO1, indicating its ability to induce antioxidant and cytoprotective enzymes.	Br J Pharmacol. 2011 Aug;163(8):1653-65
HepG2 cells	30 µM	12-24 hours	Sauchinone significantly increased the mRNA and protein levels of GCL and NQO1, indicating its induction of antioxidant enzymes via activation of the Nrf2 pathway.	Br J Pharmacol. 2011 Aug;163(8):1653-65
Human liver microsomes (HLMs)	0-200 µM	15 or 60 minutes	Evaluated the inhibitory effect of Sauchinone on UGT1A1, 1A3, 1A6, and 2B7 activities, with IC50 values of 8.83, 43.9, 0.758, and 0.279 μM, respectively	Molecules. 2018 Feb 9;23(2):366
Human liver microsomes (HLMs)	0-200 µM	15 or 60 minutes	Evaluate the inhibitory effect of Sauchinone on UGT1A1, 1A3, 1A6, and 2B7 activities, with IC50 values of 8.83, 43.9, 0.758, and 0.279 μM respectively	Molecules. 2018 Feb 9;23(2):366
Microglial BV-2 cells	1, 5, and 10 µM	24 hours	Inhibited LPS-induced inflammatory responses, reduced ROS and NO generation, and decreased iNOS and COX-2 expression	J Neuroinflammation. 2014 Jul 2;11:118
Astrocytes	1, 5, and 10 µM	24 hours	Inhibited LPS-induced inflammatory responses, reduced ROS and NO generation, and decreased iNOS and COX-2 expression	J Neuroinflammation. 2014 Jul 2;11:118
Microglial BV-2 cells	1, 5, and 10 µM	24 hours	To investigate the inhibitory effect of ent-Sauchinone on LPS-induced inflammatory responses, results showed that ent-Sauchinone significantly reduced ROS and NO generation and iNOS and COX-2 expression.	J Neuroinflammation. 2014 Jul 2;11:118
Astrocytes	1, 5, and 10 µM	24 hours	To investigate the inhibitory effect of ent-Sauchinone on LPS-induced inflammatory responses, results showed that ent-Sauchinone significantly reduced ROS and NO generation and iNOS and COX-2 expression.	J Neuroinflammation. 2014 Jul 2;11:118
Mouse primary hepatocytes	10, 100 µM	24 hours	Sauchinone inhibits PCSK9 expression in mouse primary hepatocytes.	Sci Rep. 2018 Apr 30;8(1):6737
HepG2 cells	10, 20, 100 µM	24 hours	Sauchinone regulates cholesterol metabolism by downregulating PCSK9 expression and upregulating LDLR expression, thereby increasing LDL-C uptake.	Sci Rep. 2018 Apr 30;8(1):6737
Mouse primary hepatocytes	10, 100 µM	24 hours	Sauchinone inhibited PCSK9 expression.	Sci Rep. 2018 Apr 30;8(1):6737
HepG2 cells	10, 20, 100 µM	24 hours	Sauchinone downregulated PCSK9 expression and upregulated LDLR expression, increasing LDL-C uptake.	Sci Rep. 2018 Apr 30;8(1):6737
Human liver microsomes	0-300 µM	30 minutes	Evaluation of reversible inhibition of Sauchinone on CYP2B6, 2C19, 2E1, and 3A4, showing non-competitive inhibition with Ki values of 14.3, 16.8, 41.7, and 6.84 μM, respectively	Molecules. 2018 Mar 2;23(3):555
Human liver microsomes (HLMs)	0-300 µM	30 minutes	Sauchinone reversibly inhibited CYP2B6, 2C19, 2E1, and 3A4 activities with Ki values of 14.3, 16.8, 41.7, and 6.84 μM, respectively.	Molecules. 2018 Mar 2;23(3):555
Human liver microsomes	0-300 µM	30 minutes pre-incubation, 10 minutes incubation	Evaluation of time-dependent inhibition of Sauchinone on CYP2B6, 2E1, and 3A4, with IC50 shifts of 9.28, 20.9, and 21.4-fold, respectively	Molecules. 2018 Mar 2;23(3):555
Human liver microsomes (HLMs)	0-300 µM	30-min pre-incubation	Sauchinone time-dependently inhibited CYP2B6, 2E1, and 3A4 activities with IC50 shifts of 9.28, 20.9, and 21.4-fold, respectively.	Molecules. 2018 Mar 2;23(3):555
Human renal mesangial cells	0.1–1 µM	48 hours	To investigate the effect of Sauchinone on AngII-induced proliferation of renal mesangial cells. Results showed that Sauchinone inhibited AngII-induced cell proliferation in a dose-dependent manner.	Int J Mol Sci. 2020 Sep 23;21(19):7003
MTV/TM-011 cells	12.5, 25, 50 µM	48 hours	To evaluate the effect of sauchinone on cell viability, results showed that sauchinone significantly inhibited the viability of breast cancer cells in a dose-dependent manner.	Biosci Rep. 2021 Oct 29;41(10):BSR20211067
MDA-MB-231 cells	12.5, 25, 50 µM	48 hours	To evaluate the effect of sauchinone on cell viability, results showed that sauchinone significantly inhibited the viability of breast cancer cells in a dose-dependent manner.	Biosci Rep. 2021 Oct 29;41(10):BSR20211067
Human renal mesangial cells	0.1–1 µM	48 hours	To investigate the effect of Sauchinone on AngII-induced proliferation of renal mesangial cells. Results showed that Sauchinone inhibited AngII-induced cell proliferation in a dose-dependent manner.	Int J Mol Sci. 2020 Sep 23;21(19):7003
MTV/TM-011 cells	12.5, 25, 50 µM	48 hours	To evaluate the effect of sauchinone on breast cancer cell viability. Results showed that sauchinone significantly inhibited the viability of breast cancer cells in a dose-dependent manner.	Biosci Rep. 2021 Oct 29;41(10):BSR20211067
MDA-MB-231 cells	12.5, 25, 50 µM	48 hours	To evaluate the effect of sauchinone on breast cancer cell viability. Results showed that sauchinone significantly inhibited the viability of breast cancer cells in a dose-dependent manner.	Biosci Rep. 2021 Oct 29;41(10):BSR20211067
MCF-10A cells	25, 50 µM	72 hours	To evaluate the effect of sauchinone on normal breast cell viability. Results showed that sauchinone at 25 and 50 μM concentrations did not significantly affect the viability of MCF-10A cells.	Biosci Rep. 2021 Oct 29;41(10):BSR20211067

Rats	Myocardial ischemia/reperfusion injury model	Intraperitoneal injection	10 mg/kg	Single dose, lasted until the end of the experiment	To investigate the protective effect of Sauchinone against myocardial ischemia/reperfusion injury and its mechanism. Results showed that Sauchinone significantly reduced the infarct size and inhibited the phosphorylation of p38 and JNK, but had no effect on the phosphorylation of ERK1/2, Akt, and GSK-3β.	J Korean Med Sci. 2012 May;27(5):572-5
Rats	Myocardial ischemia/reperfusion injury model	Intraperitoneal injection	10 mg/kg	Single dose, lasting until 2 hours after reperfusion	To investigate the protective effect of Sauchinone against myocardial ischemia/reperfusion injury and its mechanism. Results showed that Sauchinone significantly reduced the infarct size and inhibited the phosphorylation of p38 and JNK, but had no effect on the phosphorylation of ERK1/2, Akt, and GSK-3β.	J Korean Med Sci. 2012 May;27(5):572-5
Mice	ICR mice	Oral	100 mg/kg	Single dose	Co-administration with sauchinone increased systemic exposure of sibutramine, clopidogrel, and chlorzoxazone by 23.6%, 31.0%, and 61.1%, respectively.	Molecules. 2018 Mar 2;23(3):555
Mice	Institute of Cancer Research mice	Oral and intravenous administration	100 mg/kg Sauchinone orally, 15 mg/kg Zidovudine intravenously	Single dose, observed for 480 minutes	Evaluated the inhibitory effect of Sauchinone on UGT2B7-mediated zidovudine metabolism, showing increased systemic exposure of zidovudine	Molecules. 2018 Feb 9;23(2):366
Mice	Institute of Cancer Research mice	Oral and intravenous administration	100 mg/kg Sauchinone orally, 15 mg/kg Zidovudine intravenously	Single dose, observed for 480 minutes	Evaluate the inhibitory effect of Sauchinone on UGT2B7-mediated zidovudine metabolism, results showed Sauchinone increased systemic exposure of zidovudine	Molecules. 2018 Feb 9;23(2):366
ICR mice	High-fat diet-induced obese mouse model	Oral	100 mg/kg/day	Once daily for 15 days	Sauchinone increases hepatic LDLR expression through PCSK9 inhibition, reduces serum LDL-C levels, and improves hepatic steatosis and lipid metabolism in high-fat diet-induced obese mice.	Sci Rep. 2018 Apr 30;8(1):6737
ICR and C57BL/6 mice	High-fat diet-induced obese mouse model	Oral	100 mg/kg/day	Once daily for 15 days	Sauchinone increased hepatic LDLR expression through PCSK9 inhibition, reducing serum LDL-C levels.	Sci Rep. 2018 Apr 30;8(1):6737
Mice	Acetaminophen (APAP)-induced liver injury model	Oral	30 mg/kg	Once daily for 3 days	Pretreatment with sauchinone significantly inhibited the increase in plasma ALT, AST, and LDH activities caused by APAP and reduced hemorrhage and necrosis in the central area of the liver, indicating its protective effect against APAP-induced liver injury. This effect was abolished in Nrf2 knockout mice, demonstrating its dependence on Nrf2 activation.	Br J Pharmacol. 2011 Aug;163(8):1653-65
Mice	APAP-induced liver injury model	Oral	30 mg/kg	Once daily for 3 days	Sauchinone pretreatment significantly reduced the increase in plasma ALT, AST, and LDH activities induced by APAP and alleviated histopathological liver damage. These protective effects were absent in Nrf2 knockout mice, indicating that sauchinone exerts hepatoprotective effects via the Nrf2 pathway.	Br J Pharmacol. 2011 Aug;163(8):1653-65
C57BL/6 mice	DSS-induced ulcerative colitis model	Intragastric administration	Low-dose (5 μg/g), middle-dose (10 μg/g), and high-dose (20 μg/g)	Once every 2 days until the end of the experiment	Sauchinone alleviated pathological symptoms, inhibited inflammation, and prevented mucosal barrier damage in DSS-induced UC mice. It also inhibited the NF-κB pathway by upregulating NQO1. Additionally, sauchinone regulated the diversity and composition of the gut microbiota in mice.	Front Microbiol. 2023 Jan 9;13:1084257
C57BL/6 mice	DSS-induced ulcerative colitis model	Intragastric administration	Low-dose (5 μg/g), middle-dose (10 μg/g), high-dose (20 μg/g)	Once every 2 days for 7 days	Evaluate the therapeutic effect of sauchinone on DSS-induced ulcerative colitis, results showed that sauchinone alleviated pathological symptoms, inhibited inflammation, and prevented mucosal barrier damage.	Front Microbiol. 2023 Jan 9;13:1084257

{[proInfo.proName]}

CAS No.: 177931-17-8

{[proInfo.proName]}

CAS No.: 177931-17-8

Alternative Products

Product Details of Sauchinone

Safety of Sauchinone

Related Pathways of Sauchinone

Isoform Comparison

Biological Activity

Protocol

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.81mL 0.56mL 0.28mL	14.03mL 2.81mL 1.40mL	28.06mL 5.61mL 2.81mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed